- Cardiovascular diseases are costing the U.S. $1 billion per day in medical fees and productivity losses
- The number of heart attacks is increasing on an annual basis, highlighting the importance of early detection technology
- Zenosense is developing a handheld device that could significantly lower cardiovascular-related death rate and associated medical costs by enabling swift, accurate diagnostic
Health care technology company Zenosense, Inc. (OTC: ZENO) has announced the successful completion of a second round of testing for its MIDS Cardiac™ detection technology – a handheld system designed to rapidly test for certain cardiac biomarkers at the point of care, saving medical personnel crucial time in time-sensitive situations.
Diagnostic devices play a major role in the growth and expansion of the medical technology sector (http://ibn.fm/13GIN). Under development by the company’s MIDS Medical Limited (“MML”) joint venture based at the prestigious Sci-Tech Daresbury campus in the United Kingdom, MIDS Cardiac is a patented handheld POC technology for the detection of heart attack. It is designed to help medical staff rapidly diagnose heart attack at an early stage and improve treatment and patient outcomes. Through the early detection of certain cardiac event biomarkers, MIDS Cardiac is expected to significantly accelerate the triage, diagnosis, treatment and disposition of patients reporting chest pain suspected as symptomatic of a heart attack.
In a news release announcing breakthrough quantitative testing results (http://ibn.fm/UMiEP), Zenosense reported revisions and improvements to the core MIDS technology’s sensor electronics, materially improving on previous electronics testing results announced in 2017. In addition, the sensitivity of the MIDS technology electronics has been nearly doubled.
In 2017, the first next generation troponin assay for the early detection of heart attacks was approved by the FDA for use in the U.S. High sensitivity (HS) troponin assays have long been in use in the rest of the world. Such assays have to be performed on state of the art lab analyzers that are incredibly expensive. The aim of Zenosense is to deliver a handheld device capable of detecting and measuring diagnostic assay beads to support HS troponin assays in the emergency room and clinical settings. Such handheld devices will also prove to be invaluable for the work of paramedics on the go. As a part of the 2018 testing, Zenosense has managed to improve MIDS technology electronics and carry out independent third-party verification of bead numbers.
In a news release, MML managing director and Chief Scientific Officer Dr. Nasser Djennati noted that the project is hugely challenging. “The results of this second round of testing are quite extraordinary, as magnetic detection at this level for this application is unheard of,” he added. The next key step in the development of the technology will be testing microfluidic detection on the revised electronic platform.
Heart disease is a leading cause of death in the Western world. Approximately 610,000 people in the U.S. die of heart disease every single year (http://ibn.fm/4mYXf) – one in four deaths in the country. Nearly 735,000 Americans have a heart attack each year. Cardiovascular disease, including heart attacks and strokes, costs America nearly $1 billion a day in medical fees and lost productivity, according to a CDC Foundation study (http://ibn.fm/Ag7cE). Annual medical costs related with cardiovascular diseases are likely to reach $818 billion, while productivity losses could go over $275 billion by 2030, the same study shows.
According to the World Health Organization, early detection is one of the most important prerequisites for the successful management of cardiovascular problems.
With detection equal or superior to state of the art laboratory analyzers and advanced portability allowing it to be used at point of care, including in an emergency setting, MIDS Cardiac™ would be an absolute game changer which could help save lives and money by enabling a swift diagnosis with previously unheard of accuracy at the point of care (http://ibn.fm/GxOTH).
For more information, visit the company’s website at www.Zenosense.com
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.